KRAS and pancreatic neoplasm: Investigations show that these exosomes have shRNA or siRNA that inhibits the expression of oncogenic KRAS. The results of this study show that the expression level of KRASG12D in the pancreatic cancer cell line treated with these exosomes has decreased (163).